Contrast media (CM) are widely used substances that may lead to hypersensitivity reactions. Those adverse events can be classified as immediate reactions that occur within the first hour after administration of CM or delayed reactions that develop after more than one hour and during the following 7 days. The pathomechanisms for both types of reactions are still not fully clear. Only in a minority of cases with immediate reactions an IgE-mediated pathway has been shown. In most cases, different mechanisms lead to the release of histamine and other mediators, thus provoking the symptoms of anaphylaxis. These reactions may either occur immediately after CM-injection or delayed. Moreover, some of the delayed reactions seem to be mainly T-cell mediated. Antihistamines are used in the treatment of adverse reactions as well as in the prophylaxis for patients with a history of a hypersensitivity reaction. Although the clinical aspect of frequently occurring reactions like urticaria, and angioedema (type I-reactions and type I-like reactions) implicates a first line application for antihistamines, the clinical experience shows that some cases do not respond to these agents. Therefore, it seems likely that other mediators such as leukotrienes might be involved in mediating CM-induced reactions.
Keywords: Contrast media, hypersensitivity, immediate reactions, delayed reactions, treatment, prophylaxis
Update on Sensitivity to Nonsteroidal Antiinflammatory Drugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Immediate Hypersensitivity Reactions to Penicillins and Other Betalactams
Current Pharmaceutical Design Diagnosing β-Lactam Hypersensitivity
Current Pharmaceutical Design Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Current Pharmaceutical Design Structure Function Analysis of Serpin Super-Family: "A Computational Approach"
Protein & Peptide Letters Human Plasma Kallikrein-Kinin System: Physiological and Biochemical Parameters
Cardiovascular & Hematological Agents in Medicinal Chemistry Engineered Protein Protease Inhibitors
Current Enzyme Inhibition Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema – An Overlooked Adverse Drug Reaction?
Current Diabetes Reviews Hypersensitivity to Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Current Pharmaceutical Design Hypersensitivity Reactions to Complementary and Alternative Medicine Products
Current Pharmaceutical Design Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design Antihistamine Use in Dermatologic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Substituted Benzimidazole Derivatives as Angiotensin II -AT1 Receptor Antagonist: A Review
Mini-Reviews in Medicinal Chemistry The Acquired Deficiency of C1-Inhibitor: Lymphoproliferation and Angioedema
Current Molecular Medicine Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach
Current Vascular Pharmacology Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety Treatment of Hereditary Angioedema: Current Perspectives
Recent Patents on Inflammation & Allergy Drug Discovery